SUBSCRIBE
SUBSCRIBE
News   Drug Development

Biogen Idec, Inc. (Massachusetts) Initiates Phase III Clinical Program Of Oral Compound BG-12 For Multiple Sclerosis

January 9, 2007 | 
1 min read
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen Idec (NASDAQ: BIIB) announced today that it has initiated the Phase III clinical program of BG-12, an oral fumarate in development for relapsing-remitting multiple sclerosis (MS).
Clinical research Phase III
Biogen
MORE ON THIS TOPIC
Contemporary art collage of a hand holding scissors. Copy space for ad. Modern design.
Regulatory
Krystal Cuts Melanoma Study of Viral Immunotherapy as FDA ‘Uncertainty’ Muddies Approval Pathway
August 22, 2025
 · 
2 min read
 · 
Tristan Manalac
Abstract creative art collage, market declines in the stock market. The concept of collapse or bankruptcy.
Weight loss
Viking Crashes as Obesity Pill Delivers Over 12% Weight Loss
August 19, 2025
 · 
2 min read
 · 
Tristan Manalac
Hands in black and white dropping a collection of pills on a pink background
Manufacturing
Oral Wegovy’s Pending Approval Puts Spotlight on Viability of High-Dose Peptides
August 19, 2025
 · 
5 min read
 · 
Nick Paul Taylor
Poster sketch image artwork photo collage of body language finger showing gesture symbol thumb down dislike dissatisfied minus no opinion.
Sickle cell disease
Pfizer’s $5.4B GBT Bet Disappoints Again as Sickle Cell Therapy Fails in Phase III
August 18, 2025
 · 
2 min read
 · 
Tristan Manalac